Clinical Trial Result Information
- Protocol number:
- BO21223
- Title of Study:
- A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
- Sponsor:
- Hoffmann-La Roche
- Company division:
- Pharmaceutical
- Product name:
- RO5072759
- Therapeutic area:
-
- Non-Hodgkin's Lymphoma
- Clinical study summary:
- This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.
- Phase of development:
- III
- Date of report:
- To be Published
About This Database
This database is populated with information on the results of Roche-sponsored clinical trials.